Mechanisms of diabetic cardiomyopathy: Focus on inflammation
Myriam Bellemare(Montreal Heart Institute), Nadia Bouabdallaoui(Montreal Heart Institute), Eileen O’Meara(Montreal Heart Institute), Liane Bourcier(Montreal Heart Institute), Jacinthe Boulet(Montreal Heart Institute), Josep Iglésies(Montreal Heart Institute)
Cited by 32
Related Papers
Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction
|New England Journal of Medicine|2019|6.8k
Regional Variation in Patients and Outcomes in the Treatment of Preserved Cardiac Function Heart Failure With an Aldosterone Antagonist (TOPCAT) Trial
|Circulation|2014|1k
Influence of ejection fraction on outcomes and efficacy of spironolactone in patients with heart failure with preserved ejection fraction
|European Heart Journal|2015|524
Colchicine for community-treated patients with COVID-19 (COLCORONA): a phase 3, randomised, double-blinded, adaptive, placebo-controlled, multicentre trial
|The Lancet Respiratory Medicine|2021|271
Inflammation in heart failure: pathophysiology and therapeutic strategies
|Inflammation Research|2024|129